Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma 5Lymphoma, B-Cell 3Leukemia 3Recurrence 2Lymphoma, Mantle-Cell 2Solid Tumors 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Indolent Non-Hodgkin's Lymphoma 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Disease 1Colorectal Neoplasms 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1B-cell Malignancies 1

Interventions

Fulvestrant 3Alpelisib 3duvelisib 2Cetuximab 2volagidemab 1talazoparib 1ruxolitinib 1parsaclisib 1olaparib 1obinutuzumab 1lorlatinib 1encorafenib 1dapagliflozin 1cobimetinib 1chiauranib 1binimetinib 1avelumab 1Vemurafenib 1SF 1126 1Rituximab 1NVP-BKM120 1Drug Therapy 1CYH33 1Aspirin 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hereditary Sensory and Autonomic Neuropathies × obinutuzumab × Clear all
NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

SecuraBio

Phase 1 Terminated
3 enrolled
LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡